Sigma Healthcare (ASX:SIG) 3-Year Revenue Growth Rate : -0.30% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Sigma Healthcare 3-Year Revenue Growth Rate?

Sigma Healthcare's Revenue per Share for the six months ended in Jan. 2024 was A$1.66.

During the past 12 months, Sigma Healthcare's average Revenue per Share Growth Rate was -8.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -0.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Sigma Healthcare was 61.60% per year. The lowest was -10.20% per year. And the median was 5.20% per year.

Competitive Comparison of Sigma Healthcare's 3-Year Revenue Growth Rate

For the Medical Distribution subindustry, Sigma Healthcare's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sigma Healthcare's 3-Year Revenue Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sigma Healthcare's 3-Year Revenue Growth Rate falls into.

Sigma Healthcare 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Sigma Healthcare (ASX:SIG) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Sigma Healthcare 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Sigma Healthcare's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigma Healthcare (ASX:SIG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sigma Healthcare Ltd (ASX:SIG) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

S5YA:Germany

Address

2125 Dandenong Road, Level 6, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.sigmahealthcare.com.au

Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.